Arcus Biosciences(RCUS) - 2025 Q2 - Quarterly Results

Exhibit 99.1 HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. "We have now presented data from over 125 patients treated with casdatifan monotherapy o ...